Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mesut Remzi

Showing results (51-60 of 170) with videos related to

Pageof 17
Sort By:
Current Opinion in Urology|May 9, 2021
Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysisFahad Quhal, Keiichiro Mori, Mesut Remzi, et al.
Current Opinion in Urology|November 1, 2021
Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysisFahad Quhal, Keiichiro Mori, Harun Fajkovic, et al.
World Journal of Urology|August 31, 2011
Age-specific PCA3 score reference values for diagnosis of prostate cancerTobias Klatte, Matthias Waldert, Michela de Martino, et al.
Reviews in Urology|September 21, 2006
What's New in Prostate Cancer, Benign Prostatic Hyperplasia, and Minimally Invasive Surgery?: Highlights from the XIXth Congress of the European Association of Urology, March 23-27, 2004, Vienna, AustriaTheodore Anagnostou, Yan Kit Fong, Mesut Remzi, et al.
Current Opinion in Urology|March 20, 2021
Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?Manuela Schmidinger, Irene Resch, Harun Fajkovic, et al.
European Urology|March 15, 2006
Nephrovesical subcutaneous ureteric bypass: long-term results in patients with advanced metastatic disease-improvement of renal function and quality of lifeJoerg Schmidbauer, Christian Kratzik, Hans Christoph Klingler, et al.
European Journal of Radiology|May 27, 2006
Percutaneous radiofrequency ablation of renal tumors: midterm results in 16 patientsMazda Memarsadeghi, Theresia Schmook, Mesut Remzi, et al.
European Urology|August 14, 2009
Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladderJoerg Schmidbauer, Mesut Remzi, Tobias Klatte, et al.
World Journal of Urology|September 28, 2012
Results and outcomes after endoscopic treatment of upper urinary tract carcinoma: the Austrian experienceHarun Fajkovic, Tobias Klatte, Udo Nagele, et al.
BJU International|September 11, 2008
Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCCMatthias Waldert, Andrea Haitel, Michael Marberger, et al.
Pageof 17

Showing results (51-60 of 170) with videos related to

Sort By:
Pageof 17
Current Opinion in Urology|May 9, 2021
Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysisFahad Quhal, Keiichiro Mori, Mesut Remzi, et al.
Current Opinion in Urology|November 1, 2021
Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysisFahad Quhal, Keiichiro Mori, Harun Fajkovic, et al.
World Journal of Urology|August 31, 2011
Age-specific PCA3 score reference values for diagnosis of prostate cancerTobias Klatte, Matthias Waldert, Michela de Martino, et al.
Reviews in Urology|September 21, 2006
What's New in Prostate Cancer, Benign Prostatic Hyperplasia, and Minimally Invasive Surgery?: Highlights from the XIXth Congress of the European Association of Urology, March 23-27, 2004, Vienna, AustriaTheodore Anagnostou, Yan Kit Fong, Mesut Remzi, et al.
Current Opinion in Urology|March 20, 2021
Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?Manuela Schmidinger, Irene Resch, Harun Fajkovic, et al.
European Urology|March 15, 2006
Nephrovesical subcutaneous ureteric bypass: long-term results in patients with advanced metastatic disease-improvement of renal function and quality of lifeJoerg Schmidbauer, Christian Kratzik, Hans Christoph Klingler, et al.
European Journal of Radiology|May 27, 2006
Percutaneous radiofrequency ablation of renal tumors: midterm results in 16 patientsMazda Memarsadeghi, Theresia Schmook, Mesut Remzi, et al.
European Urology|August 14, 2009
Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladderJoerg Schmidbauer, Mesut Remzi, Tobias Klatte, et al.
World Journal of Urology|September 28, 2012
Results and outcomes after endoscopic treatment of upper urinary tract carcinoma: the Austrian experienceHarun Fajkovic, Tobias Klatte, Udo Nagele, et al.
BJU International|September 11, 2008
Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCCMatthias Waldert, Andrea Haitel, Michael Marberger, et al.
Pageof 17